PMC:7696151 / 69300-69520 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1973","span":{"begin":12,"end":20},"obj":"Species"},{"id":"1992","span":{"begin":54,"end":57},"obj":"Chemical"}],"attributes":[{"id":"A1973","pred":"tao:has_database_id","subj":"1973","obj":"Tax:9606"},{"id":"A1992","pred":"tao:has_database_id","subj":"1992","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"g in 81% of patients after four weeks [127]. Although HCQ is effective and well-tolerated, other therapeutic alternatives have emerged in recent years. Among them, monoclonal antibodies are the most promising. In a multi"}

{"project":"LitCovid-sentences","denotations":[{"id":"T441","span":{"begin":45,"end":151},"obj":"Sentence"},{"id":"T442","span":{"begin":152,"end":209},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"g in 81% of patients after four weeks [127]. Although HCQ is effective and well-tolerated, other therapeutic alternatives have emerged in recent years. Among them, monoclonal antibodies are the most promising. In a multi"}